fbn2  (Proteintech)

Journal: Fujita Medical Journal

Article Title: Phosphate overload via the type III Na-dependent Pi transporter represses aortic wall elastic fiber formation

doi: 10.20407/fmj.2023-004

Figure Lengend Snippet: Col1a1 , Eln , Fbn1 , Fbn2 , MGP , and Runx-2 gene expression in thoracic descending aortae of type III phosphate transporter transgenic (TG) rats (n=6) (open bar) and their wild-type littermates (WT) (n=6) (closed bar) at 8 weeks old. (A) Col1a1 , (B) Eln , (C) Fbn1 , (D) Fbn2 , (E) MGP , and (F) Runx-2 ). * p <0.05 was considered significant.

Article Snippet: The assay IDs of TaqMan probes used for qRT-PCR were as follows: rat collagen type 1 ( Col1a1 ), Rn01463848_m1; rat elastin ( Eln ), Rn01499782_m1; rat fibrillin-1 ( Fbn1 ), Rn01514895_m1; rat fibrillin-2 ( Fbn2 ), Rn00582832_m1; rat matrix Gla protein ( MGP ), Rn00563463_m1; rat Runt-related transcription factor 2 ( Runx-2 ), Rn01512298_m1; and rat GAPDH , Rn01775763_g1.

Techniques: Gene Expression, Transgenic Assay

Journal: Scientific Reports

Article Title: Intravitreal injection of fibrillin 2 (Fbn2) recombinant protein for therapy of retinopathy in a retina-specific Fbn2 knock-down mouse model

doi: 10.1038/s41598-023-33886-6

Figure Lengend Snippet: Retinal electroretinogram measurements (mean ± standard deviation).

Article Snippet: Primary antibodies against FBN2 (mouse# sc-393968,1:1000, Santa Cruz Biotechnology, USA), TGF (1:2000, Rabbit, ab215715, Abcam Co., Cambridge, MA, USA), LTBP-1 (Rabbit, 1:1000, ab78294, Abcam Co., Cambridge, MA, USA), and β-actin (dilution 1:10,000, Bioss antibodies, Beijing, China) were incubated overnight with the membranes at 4 °C.

Techniques:

Journal: Scientific Reports

Article Title: Intravitreal injection of fibrillin 2 (Fbn2) recombinant protein for therapy of retinopathy in a retina-specific Fbn2 knock-down mouse model

doi: 10.1038/s41598-023-33886-6

Figure Lengend Snippet: Electroretinographical analysis after intravitreal injection with empty carrier, AAV-sh-fbn2 or Fbn2 recombinant protein. NC group: Animals without intervention. AAV-NC group: Animals with an intravitreal injection of AAV empty vector and without any further treatment. AAV-sh-fbn2 group: Animals with an intravitreal injection of AAV-sh-fbn2 and without any further treatment. Fbn2-0.30 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 0.30 μg. Fbn2-0.75 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 0.75 μg. Fbn2-1.5 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 1.50 μg. Fbn2-3.0 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 3.00 μg.

Article Snippet: Primary antibodies against FBN2 (mouse# sc-393968,1:1000, Santa Cruz Biotechnology, USA), TGF (1:2000, Rabbit, ab215715, Abcam Co., Cambridge, MA, USA), LTBP-1 (Rabbit, 1:1000, ab78294, Abcam Co., Cambridge, MA, USA), and β-actin (dilution 1:10,000, Bioss antibodies, Beijing, China) were incubated overnight with the membranes at 4 °C.

Techniques: Injection, Recombinant, Plasmid Preparation

Journal: Scientific Reports

Article Title: Intravitreal injection of fibrillin 2 (Fbn2) recombinant protein for therapy of retinopathy in a retina-specific Fbn2 knock-down mouse model

doi: 10.1038/s41598-023-33886-6

Figure Lengend Snippet: Fundus retinal imaging captured by SLO and OCT in NC, AAV-NC, AAV-sh-fbn2, Fbn2-0.30 μg, Fbn2-0.75 μg, Fbn2-1.50 μg and Fbn2-3.0 μg group mice. SLO showed irregular yellow-white exudates in the retina (Black arrow). OCT shows that light reflection in each layer of the retina becomes more irregular and reflectance decreases (Yellow arrow). NC group: Animals without intervention. AAV-NC group: Animals with an intravitreal injection of AAV empty vector and without any further treatment. AAV-sh-fbn2 group: Animals with an intravitreal injection of AAV-sh-fbn2 and without any further treatment. Fbn2-0.30 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 0.30 μg. Fbn2-0.75 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 0.75 μg. Fbn2-1.5 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 1.50 μg. Fbn2-3.0 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 3.00 μg.

Article Snippet: Primary antibodies against FBN2 (mouse# sc-393968,1:1000, Santa Cruz Biotechnology, USA), TGF (1:2000, Rabbit, ab215715, Abcam Co., Cambridge, MA, USA), LTBP-1 (Rabbit, 1:1000, ab78294, Abcam Co., Cambridge, MA, USA), and β-actin (dilution 1:10,000, Bioss antibodies, Beijing, China) were incubated overnight with the membranes at 4 °C.

Techniques: Imaging, Injection, Plasmid Preparation, Recombinant

Journal: Scientific Reports

Article Title: Intravitreal injection of fibrillin 2 (Fbn2) recombinant protein for therapy of retinopathy in a retina-specific Fbn2 knock-down mouse model

doi: 10.1038/s41598-023-33886-6

Figure Lengend Snippet: Retina thickness measurements (mean ± standard deviation).

Article Snippet: Primary antibodies against FBN2 (mouse# sc-393968,1:1000, Santa Cruz Biotechnology, USA), TGF (1:2000, Rabbit, ab215715, Abcam Co., Cambridge, MA, USA), LTBP-1 (Rabbit, 1:1000, ab78294, Abcam Co., Cambridge, MA, USA), and β-actin (dilution 1:10,000, Bioss antibodies, Beijing, China) were incubated overnight with the membranes at 4 °C.

Techniques:

Journal: Scientific Reports

Article Title: Intravitreal injection of fibrillin 2 (Fbn2) recombinant protein for therapy of retinopathy in a retina-specific Fbn2 knock-down mouse model

doi: 10.1038/s41598-023-33886-6

Figure Lengend Snippet: Retinal thickness imaging captured by OCT in NC, AAV-NC, AAV-sh-fbn2, Fbn2-0.30 μg, Fbn2-0.75 μg, Fbn2-1.50 μg and Fbn2-3.0 μg group mice. ( A ). Retinal thickness was measured at 3000 μm from optic disc (inferior, nasal, temporal, and superior) ( B ).NC group: Animals without intervention. AAV-NC group: Animals with an intravitreal injection of AAV empty vector and without any further treatment. AAV-sh-fbn2 group: Animals with an intravitreal injection of AAV-sh-fbn2 and without any further treatment. Fbn2-0.30 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 0.30 μg. Fbn2-0.75 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 0.75 μg. Fbn2-1.5 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 1.50 μg. Fbn2-3.0 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 3.00 μg.

Article Snippet: Primary antibodies against FBN2 (mouse# sc-393968,1:1000, Santa Cruz Biotechnology, USA), TGF (1:2000, Rabbit, ab215715, Abcam Co., Cambridge, MA, USA), LTBP-1 (Rabbit, 1:1000, ab78294, Abcam Co., Cambridge, MA, USA), and β-actin (dilution 1:10,000, Bioss antibodies, Beijing, China) were incubated overnight with the membranes at 4 °C.

Techniques: Imaging, Injection, Plasmid Preparation, Recombinant

Journal: Scientific Reports

Article Title: Intravitreal injection of fibrillin 2 (Fbn2) recombinant protein for therapy of retinopathy in a retina-specific Fbn2 knock-down mouse model

doi: 10.1038/s41598-023-33886-6

Figure Lengend Snippet: Axial length measured by OCT. NC group: Animals without intervention. AAV-NC group: Animals with an intravitreal injection of AAV empty vector and without any further treatment. AAV-sh-fbn2 group: Animals with an intravitreal injection of AAV-sh-fbn2 and without any further treatment. Fbn2-0.30 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 0.30 μg. Fbn2-0.75 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 0.75 μg. Fbn2-1.5 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 1.50 μg. Fbn2-3.0 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 3.00 μg. NC group: Animals without intervention. AAV-NC group: Animals with an intravitreal injection of AAV empty vector and without any further treatment. AAV-sh-fbn2 group: Animals with an intravitreal injection of AAV-sh-fbn2 and without any further treatment. Fbn2-0.30 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 0.30 μg. Fbn2-0.75 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 0.75 μg. Fbn2-1.5 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 1.50 μg. Fbn2-3.0 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 3.00 μg.

Article Snippet: Primary antibodies against FBN2 (mouse# sc-393968,1:1000, Santa Cruz Biotechnology, USA), TGF (1:2000, Rabbit, ab215715, Abcam Co., Cambridge, MA, USA), LTBP-1 (Rabbit, 1:1000, ab78294, Abcam Co., Cambridge, MA, USA), and β-actin (dilution 1:10,000, Bioss antibodies, Beijing, China) were incubated overnight with the membranes at 4 °C.

Techniques: Injection, Plasmid Preparation, Recombinant

Journal: Scientific Reports

Article Title: Intravitreal injection of fibrillin 2 (Fbn2) recombinant protein for therapy of retinopathy in a retina-specific Fbn2 knock-down mouse model

doi: 10.1038/s41598-023-33886-6

Figure Lengend Snippet: Measurement of fbn2, Tgf-β1 and LTBP-1 expression at mRNA levels in the retina of mice in NC, AAV-NC, AAV-sh-fbn2, Fbn2-0.30 μg, Fbn2-0.75 μg, Fbn2-1.50 μg and Fbn2-3.0 μg groups (all groups n = 9). Data are shown as mean ± SEM. * P < 0.05 all other groups versus AAV-NC group; ** P < 0.001 all other groups versus AAV-NC group; # P < 0.05 all other groups versus AAV-sh-fbn2 group NC group: Animals without intervention. AAV-NC group: Animals with an intravitreal injection of AAV empty vector and without any further treatment. AAV-sh-fbn2 group: Animals with an intravitreal injection of AAV-sh-fbn2 and without any further treatment. Fbn2-0.30 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 0.30 μg. Fbn2-0.75 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 0.75 μg. Fbn2-1.5 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 1.50 μg. Fbn2-3.0 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 3.00 μg.

Article Snippet: Primary antibodies against FBN2 (mouse# sc-393968,1:1000, Santa Cruz Biotechnology, USA), TGF (1:2000, Rabbit, ab215715, Abcam Co., Cambridge, MA, USA), LTBP-1 (Rabbit, 1:1000, ab78294, Abcam Co., Cambridge, MA, USA), and β-actin (dilution 1:10,000, Bioss antibodies, Beijing, China) were incubated overnight with the membranes at 4 °C.

Techniques: Expressing, Injection, Plasmid Preparation, Recombinant

Journal: Scientific Reports

Article Title: Intravitreal injection of fibrillin 2 (Fbn2) recombinant protein for therapy of retinopathy in a retina-specific Fbn2 knock-down mouse model

doi: 10.1038/s41598-023-33886-6

Figure Lengend Snippet: Elisa measurement of Fbn2, Tgf-β1 and LTBP-1 expression at protein levels in retina of mice in NC, AAV-NC, AAV-sh-fbn2, Fbn2-0.30 μg, Fbn2-0.75 μg, Fbn2-1.50 μg and Fbn2-3.0 μg group (all groups n = 9). Data are shown as mean ± SEM. * P < 0.05 all other groups versus AAV-NC group; ** P < 0.001 all other groups versus AAV-NC group; # P < 0.05 all other groups versus AAV-sh-fbn2 group. NC group: Animals without intervention. AAV-NC group: Animals with an intravitreal injection of AAV empty vector and without any further treatment. AAV-sh-fbn2 group: Animals with an intravitreal injection of AAV-sh-fbn2 and without any further treatment. Fbn2-0.30 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 0.30 μg. Fbn2-0.75 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 0.75 μg. Fbn2-1.5 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 1.50 μg. Fbn2-3.0 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 3.00 μg.

Article Snippet: Primary antibodies against FBN2 (mouse# sc-393968,1:1000, Santa Cruz Biotechnology, USA), TGF (1:2000, Rabbit, ab215715, Abcam Co., Cambridge, MA, USA), LTBP-1 (Rabbit, 1:1000, ab78294, Abcam Co., Cambridge, MA, USA), and β-actin (dilution 1:10,000, Bioss antibodies, Beijing, China) were incubated overnight with the membranes at 4 °C.

Techniques: Enzyme-linked Immunosorbent Assay, Expressing, Injection, Plasmid Preparation, Recombinant

Journal: Scientific Reports

Article Title: Intravitreal injection of fibrillin 2 (Fbn2) recombinant protein for therapy of retinopathy in a retina-specific Fbn2 knock-down mouse model

doi: 10.1038/s41598-023-33886-6

Figure Lengend Snippet: Measurement of fbn2, Tgf-β1 and LTBP-1 expression at protein levels using Western blot in the retina of mice in NC, AAV-NC, AAV-sh-fbn2 and Fbn2-0.75 μg group (all groups n = 9). Data are shown as mean ± SEM. ** P < 0.001 all other groups versus AAV-NC group; # P < 0.05 all other groups versus AAV-sh-fbn2 group. Original blots are presented in Supplementary Fig. – . A: NC group, B: AAV-NC group, C: AAV-sh-fbn2 group, D: Fbn2-0.75 μg group. (** P < 0.001 compared with the AAV-NC group; # P < 0.05 compared with the AAV-sh-fbn2 group). NC group: Animals without intervention. AAV-NC group: Animals with an intravitreal injection of AAV empty vector and without any further treatment. AAV-sh-fbn2 group: Animals with an intravitreal injection of AAV-sh-fbn2 and without any further treatment. Fbn2-0.30 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 0.30 μg. Fbn2-0.75 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 0.75 μg. Fbn2-1.5 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 1.50 μg. Fbn2-3.0 μg group: Animals with an intravitreal injection of AAV-sh-fbn2, followed by an intravitreal injection of fbn2 recombinant protein in a dose of 3.00 μg.

Article Snippet: Primary antibodies against FBN2 (mouse# sc-393968,1:1000, Santa Cruz Biotechnology, USA), TGF (1:2000, Rabbit, ab215715, Abcam Co., Cambridge, MA, USA), LTBP-1 (Rabbit, 1:1000, ab78294, Abcam Co., Cambridge, MA, USA), and β-actin (dilution 1:10,000, Bioss antibodies, Beijing, China) were incubated overnight with the membranes at 4 °C.

Techniques: Expressing, Western Blot, Injection, Plasmid Preparation, Recombinant